Enhanced Permeability and Retention (EPR) Effect for Anticancer Nanomedicine Drug Targeting

  • Khaled Greish
Part of the Methods in Molecular Biology book series (MIMB, volume 624)

Abstract

Effective cancer therapy remains one of the most challenging tasks to the scientific community, with little advancement on overall cancer survival landscape during the last two decades. A major limitation inherent to most conventional anticancer chemotherapeutic agents is their lack of tumor selectivity. One way to achieve selective drug targeting to solid tumors is to exploit abnormalities of tumor vasculature, namely hypervascularization, aberrant vascular architecture, extensive production of vascular permeability factors stimulating extravasation within tumor tissues, and lack of lymphatic drainage. Due to their large size, nano-sized macromolecular anticancer drugs administered intravenously (i.v.) escape renal clearance. Being unable to penetrate through tight endothelial junctions of normal blood vessels, their concentration builds up in the plasma rendering them long plasma half-life. More importantly, they can selectively extravasate in tumor tissues due to its abnormal vascular nature. Overtime the tumor concentration will build up reaching several folds higher than that of the plasma due to lack of efficient lymphatic drainage in solid tumor, an ideal application for EPR-based selective anticancer nanotherapy. Indeed, this selective high local concentration of nano-sized anticancer drugs in tumor tissues has proven superior in therapeutic effect with minimal side effects in both preclinical and clinical settings.

Key words

EPR effect nanomedicines half-life targeted anticancer therapy macromolecular drugs tumor model in vivo biodistribution 

References

  1. 1.
    Folkman, J. (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182–1186.CrossRefPubMedGoogle Scholar
  2. 2.
    Skinner, S. A., Tutton, P. J., and O’Brien, P. E. (1990) Microvascular architecture of experimental colon tumors in the rat. Cancer Res 50, 2411–2417.PubMedGoogle Scholar
  3. 3.
    Yuan, F., Salehi, H. A., Boucher, Y., Vasthare, U. S., Tuma, R. F., and Jain, R. K. (1994) Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 54, 4564–4568.PubMedGoogle Scholar
  4. 4.
    Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1, 27–31.CrossRefPubMedGoogle Scholar
  5. 5.
    Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., and McDonald, D. M. (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156, 1363–1380.PubMedGoogle Scholar
  6. 6.
    Noguchi, Y., Wu, J., Duncan, R., Strohalm, J., Ulbrich, K., Akaike, T., and Maeda, H. (1998) Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 89, 307–314.PubMedGoogle Scholar
  7. 7.
    Wu, J., Akaike, T., and Maeda, H. (1998) Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res 58, 159–165.PubMedGoogle Scholar
  8. 8.
    Maeda, H., Akaike, T., Wu, J., Noguchi, Y., and Sakata, Y. (1996) Bradykinin and nitric oxide in infectious disease and cancer. Immunopharmacology 33, 222–230.CrossRefPubMedGoogle Scholar
  9. 9.
    Maeda, H., Matsumura, Y., and Kato, H. (1988) Purification and identification of [hydroxyprolyl3]bradykinin in ascitic fluid from a patient with gastric cancer. J Biol Chem 263, 16051–16054.PubMedGoogle Scholar
  10. 10.
    Doi, K., Akaike, T., Horie, H., Noguchi, Y., Fujii, S., Beppu, T., Ogawa, M., and Maeda, H. (1996) Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth. Cancer 77, 1598–1604.PubMedGoogle Scholar
  11. 11.
    Matsumura, Y. and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46, 6387–6392.PubMedGoogle Scholar
  12. 12.
    Seymour, L. W., Miyamoto, Y., Maeda, H., Brereton, M., Strohalm, J., Ulbrich, K., and Duncan, R. (1995) Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur J Cancer 31A, 766–770.CrossRefPubMedGoogle Scholar
  13. 13.
    Greish, K., Sawa, T., Fang, J., Akaike, T., and Maeda, H. (2004) SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours. J Control Release 97, 219–230.CrossRefPubMedGoogle Scholar
  14. 14.
    Suzuki, M., Hori, K., Abe, I., Saito, S., and Sato, H. (1981) A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J Natl Cancer Inst 67, 663–669.PubMedGoogle Scholar
  15. 15.
    Li, C. J., Miyamoto, Y., Kojima, Y., and Maeda, H. (1993) Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br J Cancer 67, 975–980.PubMedGoogle Scholar
  16. 16.
    Greish, K., Fang, J., Inutsuka, T., Nagamitsu, A., and Maeda, H. (2003) Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet 42, 1089–1105.CrossRefPubMedGoogle Scholar
  17. 17.
    Tanaka, S., Akaike, T., Wu, J., Fang, J., Sawa, T., Ogawa, M., Beppu, T., and Maeda, H. (2003) Modulation of tumor-selective vascular blood flow and extravasation by the stable prostaglandin 12 analogue beraprost sodium. J Drug Target 11, 45–52.CrossRefPubMedGoogle Scholar
  18. 18.
    Meyer, R. E., Shan, S., DeAngelo, J., Dodge, R. K., Bonaventura, J., Ong, E. T., and Dewhirst, M. W. (1995) Nitric oxide synthase inhibition irreversibly decreases perfusion in the R3230Ac rat mammary adenocarcinoma. Br J Cancer 71, 1169–1174.PubMedGoogle Scholar
  19. 19.
    Okamoto, T., Akaike, T., Sawa, T., Miyamoto, Y., van der Vliet, A., and Maeda, H. (2001) Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem 276, 29596–29602.CrossRefPubMedGoogle Scholar
  20. 20.
    Dougherty, T. J., Gomer, C. J., Henderson, B. W., Jori, G., Kessel, D., Korbelik, M., Moan, J., and Peng, Q. (1998) Photodynamic therapy. J Natl Cancer Inst 90, 889–905.CrossRefPubMedGoogle Scholar
  21. 21.
    Chen, B., Pogue, B. W., Luna, J. M., Hardman, R. L., Hoopes, P. J., and Hasan, T. (2006) Tumor vascular permeabilization by vascular-targeting photosensitization: effects, mechanism, and therapeutic implications. Clin Cancer Res 12, 917–923.CrossRefPubMedGoogle Scholar
  22. 22.
    Nozawa, H., Chiu, C., and Hanahan, D. (2008) Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 33, 12493–12498.Google Scholar
  23. 23.
    Furuya, M. and Yonemitsu, Y. (2008) Cancer neovascularization and proinflammatory microenvironments. Curr Cancer Drug Targets 4, 253–265.CrossRefGoogle Scholar
  24. 24.
    Nagamitsu, A., Inuzuka, T., Greish, K., and Maeda, H. (2007) SMANCS Dynamic therapy for various advanced solid tumors and promising clinical effects enhanced drug delivery by hydrodynamic modulation with vascular mediators, particularly angiotensin II, during arterial infusion. DDS 22, 510–522.CrossRefGoogle Scholar
  25. 25.
    Pahlman, I. and Gozzi, P. (1999) Serum protein binding of tolterodine and its major metabolites in humans and several animal species. Biopharm Drug Dispos 2, 91–99.CrossRefGoogle Scholar
  26. 26.
    Iyer, A. K., Khaled, G., Fang, J., and Maeda, H. (2006) Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 11, 812–818.CrossRefPubMedGoogle Scholar
  27. 27.
    Greish, K., Arun, I., Fang, J., and Maeda, H. (2006) Enhanced permeability and retention (EPR) effect and tumor-selective delivery of anticancer drugs. In Delivery of Protein and Peptide Drugs in Cancer. V. P. Torchilin(Ed.), Imperial College Press, London, 37–52.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Khaled Greish
    • 1
  1. 1.Department of Pharmaceuticals and Pharmaceutical Chemistry, and Utah Center for NanomedicineUniversity of UtahSalt Lake CityUSA

Personalised recommendations